INMD (InMode) — Investment Thesis #

Scored 2026-03-22 | Price: $13.53 | Composite: 2.8/5 (14/25)

Hypothesis #

InMode is an Israeli medical aesthetics company with a fortress balance sheet ($555M cash, $83M total liabilities) trading at an enterprise value of just $302M on $370M revenue with 79% gross margins. The market implies 0.48% growth for a company operating at 60% capacity due to Israel conflict disruption. If capacity normalizes, EPS should recover from $1.43 (depressed) toward $2.00-2.30 (historical), implying $18-23 fair value — 33-70% upside. This is a Graham Ch. 8 "Mr. Market" opportunity: the stock is priced for permanent impairment when the business has a temporary constraint.

Caveat: Composite score of 2.8/5 is below the typical 3.5+ threshold for a Graham buy. This is a speculative recovery play, not a core value holding. Size accordingly.

Why This Is Good #

The balance sheet #

• Cash + investments: $555M ($8.77/share — 65% of $13.53 market price)
• Total liabilities: $83M (of which $8M is capital lease — zero financial debt)
• Net cash: $472M — 55% of market cap
• EV/Revenue: 0.84x — buying a 79% gross margin business for less than 1x revenue
• P/E × P/B = 11.87 — comfortably under Graham's 22.5 ceiling

The buyback program #

• FY2024 buyback: $285M (33% of current market cap)
• FY2025 buyback: $127M (15% of current market cap)
• New $600M authorization (Mar 2026) — 70% of current market cap
• Share count reduced 23% in 3 years (82.5M → 63.4M)
• Capital allocation is aggressively shareholder-friendly

The normalized earnings potential #

• FY2023 peak EPS: $2.30, peak revenue: $492M
• Current EPS: $1.43, current revenue: $370M
• CFO disclosed 60% capacity utilization (Israel conflict)
• At 100% capacity, normalized revenue ~$600M+ and EPS ~$2.00-2.30 is plausible
• Graham IV at $2.00 EPS and 5% growth: $37 → 174% upside

Why This Is NOT A Full Graham Candidate #

Composite 2.8/5 — the lowest-scoring candidate in this pipeline. The balance sheet earns a perfect 5/5 but earnings (2/5) and dividend (1/5) drag the composite down. This is not a defensive holding.

Why Paleologo Says Quarter-Kelly #

1. High parameter uncertainty — the recovery timeline is unknown. CFO guided flat 2026 revenue. Israeli operations face unquantifiable geopolitical risk. Per Ch. 13.3, when tau^2 (uncertainty about the mean return) is large, optimal Kelly fraction shrinks dramatically.
2. Binary risk profile — the thesis works if capacity normalizes; it fails if the Israeli conflict persists or worsens. Binary outcomes with unquantifiable probability warrant minimum viable position sizes.
3. No insider signal to confirm — unlike FDBC (6:1 buying) or TGLS ($22.9M cluster buy), INMD has no insider purchase data to serve as an independent confirmation source.

Entry Plan #

WATCHLIST — do not enter until Apr 28 earnings provide signal.

Entry conditions (must meet 2 of 3):

1. Q1 2026 EPS beats $0.30 consensus
2. Management guides to capacity improvement above 70%
3. Revenue guidance raised from "flat 2026"

If conditions met: quarter-size position, single tranche. If conditions not met: remain on watchlist, re-evaluate Q2 earnings.

Exit Plan #

Fundamental stops:

• Revenue below $300M annual → EXIT
• Cash deployed on bad acquisition → EXIT
• Capacity drops below 50% → RE-SCORE
• No earnings recovery by Q3 2026 → TRIM

Red Flags #